stoxline Quote Chart Rank Option Currency Glossary
  
YS Biopharma Co., Ltd. (YS)
0.4  0 (0%)    02-27 14:27
Open: 0.4099
High: 0.412
Volume: 117,662
  
Pre. Close: 0.4
Low: 0.3814
Market Cap: 75(M)
Technical analysis
2024-02-27 2:18:17 PM
Short term     
Mid term     
Targets 6-month :  0.53 1-year :  0.61
Resists First :  0.46 Second :  0.52
Pivot price 0.4
Supports First :  0.34 Second :  0.29
MAs MA(5) :  0.4 MA(20) :  0.4
MA(100) :  0.52 MA(250) :  1.6
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  39 D(3) :  40.6
RSI RSI(14): 46.6
52-week High :  18.44 Low :  0.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ YS ] has closed below upper band by 37.8%. Bollinger Bands are 75.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.44 - 0.44 0.44 - 0.45
Low: 0.37 - 0.38 0.38 - 0.38
Close: 0.38 - 0.39 0.39 - 0.39
Company Description

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Headline News

Thu, 22 Feb 2024
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition ... - PR Newswire

Thu, 22 Feb 2024
YS Biopharma Co Announces the Results of Extraordinary General Meeting - Marketscreener.com

Thu, 22 Feb 2024
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 - Yahoo Finance

Fri, 16 Feb 2024
YS Biopharma Co., Ltd. Announces Management Changes -February 16, 2024 at 05:36 pm EST - Marketscreener.com

Fri, 16 Feb 2024
YS Biopharma Co., Ltd. Announces Chief Financial Officer Changes - Marketscreener.com

Wed, 14 Feb 2024
YS Biopharma Announces Appointment of New Directors - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 188 (M)
Shares Float 17 (M)
Held by Insiders 29.2 (%)
Held by Institutions 4.9 (%)
Shares Short 86 (K)
Shares Short P.Month 118 (K)
Stock Financials
EPS -0.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.98
Profit Margin -66.9 %
Operating Margin -117 %
Return on Assets (ttm) -12.1 %
Return on Equity (ttm) -61.7 %
Qtrly Rev. Growth -50.1 %
Gross Profit (p.s.) 0
Sales Per Share 2.97
EBITDA (p.s.) -1.41
Qtrly Earnings Growth 0 %
Operating Cash Flow -221 (M)
Levered Free Cash Flow -191 (M)
Stock Valuations
PE Ratio -0.74
PEG Ratio 0
Price to Book value 0.06
Price to Sales 0.13
Price to Cash Flow -0.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android